Navigation Links
Final Vectibix Positive Pivotal Phase 3 Trial Results In Metastatic,Colorectal Cancer Patients Published

THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Apr 30, 2007 - Amgen (NASDAQ:AMGN), today announced final results from a pivotal Phase 3 trial which showed that Vectibix(TM) (panitumumab), a fully human monoclonal antibody directed against the epidermal growth factor receptor (EGFr), prolonged progression-free survival (PFS) compared to best supportive care (BSC) in metastatic colorectal cancer patients who had failed fluoropyrimidine, irinotecan, and oxaliplatin containing chemotherapy regimens. The results were published in the May issue of the Journal of Clinical Oncology.

"Medical advances in the treatment of first- and second-line colorectal cancer have improved survival rates; however, most patients develop resistance to these therapies, creating the need for an active agent to treat patients with advanced disease," said Professor Eric Van Cutsem, M.D., Ph.D., Digestive Oncology Unit, University Hospital Gasthuisberg, Leuven, Belgium, lead author of the manuscript. "Final results from the first large randomized trial of its kind show that Vectibix provides a benefit in this heavily pre-treated patient population."

The September 2006 Food and Drug Administration (FDA) approval of Vectibix was based on the results from this multi-national, open-label, randomized study of 463 patients. Patients were randomized to receive 6 mg/kg Vectibix plus BSC (n=231) every two weeks or BSC alone (n=232) until disease progression or unacceptable toxicity. An independent, central radiology review board assessed disease progression and tumor shrinkage. BSC patients determined to have disease progression were eligible to cross-over to a separate study and receive Vectibix.

The primary endpoint of this study was an improvement in progression-free survival. Co-secondary study endpoints were best objective response by blinded central review and overall survival time. The effectiveness of Vectibix for the treatment of EGFr
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Human Genome Sciences Announces Positive Final Results Of Phase 2b Trial of Albuferon
2. Positive Final Data from HyCAMP Phase II Trial in Metastatic Colorectal
3. Intarcia Therapeutics Announces Presentation of Final Results From a Phase 2 Combination Study for the Treatment of Hepatitis C at the Digestive Disease Week Conference
4. Intarcia Therapeutics Announces Final Results From a Phase 2 Study of Injectable Omega Interferon plus Ribavirin for the Treatment of Hepatitis C Genotype-1
5. Cell Genesys Provides Final Median Survival Data From Second Phase 2 Trial of GVAX Immunotherapy for Prostate Cancer
6. Baxter Announces Final Phase I/II Data and Initiation of Phase III Clinical Trial for Candidate Pandemic H5N1 Influenza Vaccine
7. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Positive Aggrastat Results Featured in the Journal of the American College of Cardiology
9. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
Post Your Comments:
(Date:6/2/2015)... , June 2, 2015 ... and segments the concerned market with analysis and ... $261.8 million in 2014, and is estimated to ... of 19.3% from 2014 to 2019. ... Simulation Market for an analysis of industry trends ...
(Date:6/2/2015)... , June 2, 2015 BioDelivery Sciences International, Inc. ... the presentation by Dr. Mark A. Sirgo , President ... 2:30 PM Eastern time. Jefferies 2015 Global Healthcare ... Hyatt, New York City , NY ... accessed at www.bdsi.com .  For those who are not ...
(Date:6/2/2015)... -- Only a quarter of physicians who prescribe opioids say ... them to, according to new survey results released by ... and myCME , Haymarket Medical Education,s global medical ... director of BUSM,s Safe and Competent Opioid Prescribing ... a critical need for provider education addressing this issue. ...
Breaking Medicine Technology:North America Mannequin-Based Simulation Market is Expected to Reach $632.5 Million by 2019, at a CAGR of 19.3% From 2014 to 2019 2North America Mannequin-Based Simulation Market is Expected to Reach $632.5 Million by 2019, at a CAGR of 19.3% From 2014 to 2019 3BioDelivery Sciences to Present at the Jefferies 2015 Healthcare Conference - Schedule Change 2BioDelivery Sciences to Present at the Jefferies 2015 Healthcare Conference - Schedule Change 3Survey Results Show Few Doctors Are Very Confident Managing Patients on Opioids 2
... ... Jolla-, ... /PRNewswire-,FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD ), a,biopharmaceutical company ... organization, today announced,that an agreement has been executed licensing classes of ...
... The Quigley,Corporation (Nasdaq: QGLY ) announced positive ... subsidiary, Quigley Pharma Inc., which was,conducted in chickens ... The compound was administered to chicks that had ... from the study indicated,that QR448(a) is efficacious against ...
Cached Medicine Technology:Poniard Pharmaceuticals Licenses Kinase Inhibitors From The Scripps Research Institute 2Poniard Pharmaceuticals Licenses Kinase Inhibitors From The Scripps Research Institute 3Poniard Pharmaceuticals Licenses Kinase Inhibitors From The Scripps Research Institute 4Quigley Announces Successful Poultry Study of Chickens With Infectious Bronchitis; Plans to Approach the Poultry Industry for Potential Commercialization 2Quigley Announces Successful Poultry Study of Chickens With Infectious Bronchitis; Plans to Approach the Poultry Industry for Potential Commercialization 3Quigley Announces Successful Poultry Study of Chickens With Infectious Bronchitis; Plans to Approach the Poultry Industry for Potential Commercialization 4Quigley Announces Successful Poultry Study of Chickens With Infectious Bronchitis; Plans to Approach the Poultry Industry for Potential Commercialization 5
(Date:6/2/2015)... Milton Hershey School® graduate Vincent Klomps ’10 ... of the Physician Assistant Program’s entering class of 2015 ... with a white coat, which symbolizes his entrance into ... of Vincent’s accomplishments both at MHS and postgraduation,” said ... of how a top-notch education can lead to achievement ...
(Date:6/2/2015)... (PRWEB) June 02, 2015 ANT Wireless, ... the market entry of two new products implementing the ... Trainer announce new wireless interoperability in their bike trainer ... for cyclists. Tacx has implemented the FE-C device profile ... as well as its new indoor training software, while ...
(Date:6/2/2015)... MAP Health Management, LLC, a provider of outcome data, ... facilities, announced today that Jared Smith has joined the ... be responsible for developing and implementing a marketing strategy ... message, products and initiatives. , Prior to joining MAP, ... in Irving, Texas, where he was responsible for developing ...
(Date:6/2/2015)... (PRWEB) June 02, 2015 DiaTech ... drug response profiling test to help oncologists provide ... College of American Pathologists (CAP) for its laboratories ... CAP certification is equivalent to the ‘Good Housekeeping’ ... and chief executive officer for DiaTech. “It’s a ...
(Date:6/2/2015)... 2015 For those that have ever ... to harmful germs, chemicals and bodily fluids from each ... an inventor from Queens Village, N.Y., their worries are ... efficient, fun, hygienic way to store and dispense toothpaste. ... bugs, chemicals and germs. Furthermore, it insures that all ...
Breaking Medicine News(10 mins):Health News:First ANT FE-C Enabled Fitness Products Enter Market 2Health News:First ANT FE-C Enabled Fitness Products Enter Market 3Health News:Jared Smith Joins MAP Health Management, LLC, as Vice President of Marketing 2Health News:DiaTech Oncology Gains College of American Pathologists Accreditation for U.S. CorrectChemo Laboratory 2Health News:Dental Storage and Dispensing Unit Invented by InventHelp Client (LGI-1890) 2
... GE Healthcare, the leading manufacturer of 3D/4D ultrasound ... Virginia Medical School (EVMS) obstetrician that can automate the ... fetal heart defects. GE Healthcare has licensed the software ... Alfred Abuhamad, M.D., chairman of obstetrics and gynecology at ...
... Communication and Compliance Important for Addressing ... Challenges Uncovered in Survey, AVENTURA, Fla., ... (UC) consider feeling unwell to be a,normal part of life, while ... UC patients, according to results from a,nationwide series of surveys presented ...
... First Oral Pharmacologic Agent Developed for the Treatment of Premature ... ... 7 Janssen-Cilag companies in,Europe have submitted a Marketing Authorisation Application ... years,of age., Premature ejaculation is a form of male sexual ...
... more than half, CDC study finds , FRIDAY, Dec. ... receiving the pneumococcal vaccine appears to be associated with ... to a new report from the U.S. Centers for ... 7-valent pneumococcal conjugate vaccine (PDV7) became part of the ...
... battle in fighting heart disease, ... Health Corp. CEO Gary Stanton., MELBOURNE, Fla., Dec. 7 ... heart disease all,in one Natural product. Lowering unhealthy cholesterol levels is ... build up of,plaque in the arteries and the heart muscle itself. ...
... AstraZeneca,CEO, and senior management from AstraZeneca (LSE: AZN) ... the biologics field, R&D and portfolio,progress plus the ... are available now on http://www.cantos.com ., ... do is register at, http://www.cantos.com ., Cantos.com ...
Cached Medicine News:Health News:Procedure to detect fetal heart defects is first automated use of 3-D ultrasound 2Health News:Procedure to detect fetal heart defects is first automated use of 3-D ultrasound 3Health News:Nationwide Survey Reveals Differing Physician and Patient Perceptions Regarding Impact of Ulcerative Colitis on Patients' Lives 2Health News:Nationwide Survey Reveals Differing Physician and Patient Perceptions Regarding Impact of Ulcerative Colitis on Patients' Lives 3Health News:Nationwide Survey Reveals Differing Physician and Patient Perceptions Regarding Impact of Ulcerative Colitis on Patients' Lives 4Health News:Nationwide Survey Reveals Differing Physician and Patient Perceptions Regarding Impact of Ulcerative Colitis on Patients' Lives 5Health News:Nationwide Survey Reveals Differing Physician and Patient Perceptions Regarding Impact of Ulcerative Colitis on Patients' Lives 6Health News:Nationwide Survey Reveals Differing Physician and Patient Perceptions Regarding Impact of Ulcerative Colitis on Patients' Lives 7Health News:Nationwide Survey Reveals Differing Physician and Patient Perceptions Regarding Impact of Ulcerative Colitis on Patients' Lives 8Health News:Submission of Marketing Authorisation Application for Dapoxetine in Europe 2Health News:Pneumonia Vaccine Is Keeping Kids Healthier 2Health News:New Health Corp. Introduces Heart Savior(TM), the Ultimate Natural Heart Health Product 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: